Sunday, August 24, 2025

Latest

Ayr Strategies: Canaccord Raises Price Target To $60

Late last week, Canaccord raised Ayr Strategies’ (CSE: AYR.a) 12-month price target to C$60 from C$52 and reiterated their speculative buy rating on the company. This comes after a wild week in the capital markets, with cannabis companies raising nearly C$1.5 billion since the start of the new year. AYR Strategies was included in this, having raised C$157.5 million in an overnight marketed financing.

AYR Strategies currently has four analysts covering the company with a weighted 12-month price target of C$50.75. This is up from the prior average, which was C$36.50. One analyst has a strong buy rating, while another three have buy ratings.

Matt Bottomley, Canaccord’s cannabis analyst, says that AYR is now cashed up to close all pending M&A transactions and predicts that AYR will “see a meaningful bump to its historical (and already profitable) operating levels.”

The main reason for this price target raise is primarily due to Canaccord rolling forward their valuation targets as they have done with Curaleaf (upgraded to C$23.50), Cresco Labs (upgraded to C$20.50), and Trulieve (upgraded to C$75).

Bottomley says that as multiple M&A transactions are closing during the first half of 2021, they are putting less weight on their 2021 estimates and primarily focusing on 2022 estimates. He does mention however that there is considerable forecasting risk when it comes to 2022 estimates.

Bottomley also addresses the valuation and how it is very attractive compared to the basket of senior multi-state operators. AYR trades at roughly 8.1x their 2022 EV/EBITDA multiple, while the average among the seniors is 10.9x. He adds that this is on top of a “40% discount to the relative valuations of many of the leading MSOs in the space by size/scale.” Bottomley believes that AYR’s multiple will play catch up and will slowly begin to rerate on strong fundamentals and the closing of its pending M&A.

AYR is set to significantly increase its U.S. exposure with the closing of its M&A transactions. The company is currently pending close on a number of significant markets including:

  • Pennsylvania, the fastest-growing medical market in the U.S.
  • Arizona, adult-use sales commencing in Q2/21)
  • Ohio
  • New Jersey, where adult-use sales are to commence likely in the back half of this year
  • Florida, where it is competing for a top-5 market position via its pending deal for Liberty Health Sciences

Bottomley calls AYR the market leader in Nevada, which has primarily been the most significant tourist market in the U.S. Finally, he expects that that Massachusetts will provide upside in 2021, where AYR will see growth due to the impact of two-plus store openings during the calendar year alongside the commencement of recreational sales, which is most likely to happen in the near term.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

G Mining Q2 Earnings: Costing Gone Wild

Aya Gold Q2 Earnings: Production Slips Amid Ramp Up

i-80 Gold Q2 Earnings: Better, But Not Great

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Organigram: Consensus Price Target Falls To $3.55

On November 23rd, Organigram Holdings (TSX: OGI) announced its fourth quarter fiscal 2021 results. The...

Sunday, November 28, 2021, 01:18:00 PM

Canopy Growth: Analysts Anticipate Q1 Revenues Of $149 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal...

Tuesday, August 3, 2021, 03:28:00 PM

Fortuna Silver Sees BMO Cut Price Target To $6.50 Following Mixed Q4 Results

In late March Fortuna Silver Mines Inc. (TSX: FVI) reported its fourth quarter and full-year...

Saturday, April 2, 2022, 11:06:00 AM

Beacon Expects NG Energy’s Sinu-9 Approval To Arrive Soon

On August 25, NG Energy (TSXV: GASX) reported its second quarter financial results. Although there...

Monday, August 30, 2021, 11:31:00 AM

Tilray: Analysts Leave Targets Unchanged After MedMen Investment

On August 17, Tilray (NASDAQ: TLRY) made the announcement that they formed a new limited...

Thursday, August 19, 2021, 01:03:00 PM